Elisa K Boden1,2, Donna M Shows2, Michael V Chiorean1, James D Lord3,4. 1. Division of Gastroenterology, Virginia Mason Medical Center, Seattle, WA, 98101, USA. 2. Translational Program, Benaroya Research Institute at Virginia Mason Mailstop, IN-RC 1201 Ninth Avenue, Seattle, WA, 98101, USA. 3. Division of Gastroenterology, Virginia Mason Medical Center, Seattle, WA, 98101, USA. James.Lord@virginiamason.org. 4. Translational Program, Benaroya Research Institute at Virginia Mason Mailstop, IN-RC 1201 Ninth Avenue, Seattle, WA, 98101, USA. James.Lord@virginiamason.org.
Abstract
BACKGROUND/AIMS: Vedolizumab is an anti-α4β7 monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD). This exploratory study aimed to identify biomarkers associated with vedolizumab response. METHODS: Twenty-six IBD patients (15 with Crohn's, 11 with ulcerative or indeterminate colitis) initiating vedolizumab at a single center between 2014 and 2016 underwent sampling of serum and peripheral blood mononuclear cells (PBMCs) before and during vedolizumab therapy. Response was defined as steroid-free improvement in endoscopic score or Harvey-Bradshaw index/simple clinical colitis activity index (reduction greater than 3 or total less than 3). PBMCs were evaluated for immunophenotype and expression of α4β7 integrin on lymphocytes before and during vedolizumab therapy. Serum vedolizumab levels and α4β7 saturation were measured serially after induction. RESULTS: Fourteen out of 26 (54%) patients treated with vedolizumab responded to therapy. Pretreatment α4β7 expression was higher in responders on multiple subsets of T, B, and NK cells, with terminal effector memory (p = .0009 for CD4 and .0043 for CD8) and NK cells (p = .0047) best discriminating between responders and nonresponders. During therapy, log10 serum vedolizumab levels at trough were higher in responders than nonresponders (p = .0007). Conversely, the percentage of effector memory T cells with free α4β7 at trough was lower in responders than nonresponders (p < .0001). However, loss of α4β7 saturation with vedolizumab was more sensitive to low serum vedolizumab in nonresponders. CONCLUSIONS: Pretreatment α4β7 expression and α4β7 receptor saturation during maintenance therapy were identified as candidate biomarkers for vedolizumab response.
BACKGROUND/AIMS: Vedolizumab is an anti-α4β7 monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD). This exploratory study aimed to identify biomarkers associated with vedolizumab response. METHODS: Twenty-six IBDpatients (15 with Crohn's, 11 with ulcerative or indeterminate colitis) initiating vedolizumab at a single center between 2014 and 2016 underwent sampling of serum and peripheral blood mononuclear cells (PBMCs) before and during vedolizumab therapy. Response was defined as steroid-free improvement in endoscopic score or Harvey-Bradshaw index/simple clinical colitis activity index (reduction greater than 3 or total less than 3). PBMCs were evaluated for immunophenotype and expression of α4β7 integrin on lymphocytes before and during vedolizumab therapy. Serum vedolizumab levels and α4β7 saturation were measured serially after induction. RESULTS: Fourteen out of 26 (54%) patients treated with vedolizumab responded to therapy. Pretreatment α4β7 expression was higher in responders on multiple subsets of T, B, and NK cells, with terminal effector memory (p = .0009 for CD4 and .0043 for CD8) and NK cells (p = .0047) best discriminating between responders and nonresponders. During therapy, log10 serum vedolizumab levels at trough were higher in responders than nonresponders (p = .0007). Conversely, the percentage of effector memory T cells with free α4β7 at trough was lower in responders than nonresponders (p < .0001). However, loss of α4β7 saturation with vedolizumab was more sensitive to low serum vedolizumab in nonresponders. CONCLUSIONS: Pretreatment α4β7 expression and α4β7 receptor saturation during maintenance therapy were identified as candidate biomarkers for vedolizumab response.
Entities:
Keywords:
Anti-integrin; Biomarkers; Inflammatory bowel disease; Personalized medicine
Authors: Christian R Kreher; Markus T Dittrich; Robert Guerkov; Bernhard O Boehm; Magdalena Tary-Lehmann Journal: J Immunol Methods Date: 2003-07 Impact factor: 2.303
Authors: Elana A Maser; Renata Villela; Mark S Silverberg; Gordon R Greenberg Journal: Clin Gastroenterol Hepatol Date: 2006-08-22 Impact factor: 11.382
Authors: J Rodrigo Mora; Maria Rosa Bono; N Manjunath; Wolfgang Weninger; Lois L Cavanagh; Mario Rosemblatt; Ulrich H Von Andrian Journal: Nature Date: 2003-07-03 Impact factor: 49.962
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: M Rosario; N L Dirks; M R Gastonguay; A A Fasanmade; T Wyant; A Parikh; W J Sandborn; B G Feagan; W Reinisch; I Fox Journal: Aliment Pharmacol Ther Date: 2015-05-20 Impact factor: 8.171
Authors: Jean-Frédéric Colombel; Bruce E Sands; Paul Rutgeerts; William Sandborn; Silvio Danese; Geert D'Haens; Remo Panaccione; Edward V Loftus; Serap Sankoh; Irving Fox; Asit Parikh; Catherine Milch; Brihad Abhyankar; Brian G Feagan Journal: Gut Date: 2016-02-18 Impact factor: 23.059
Authors: Jurij Hanžel; Nejc Sever; Ivan Ferkolj; Borut Štabuc; Nataša Smrekar; Tina Kurent; Matic Koželj; Gregor Novak; Griet Compernolle; Sophie Tops; Ann Gils; David Drobne Journal: United European Gastroenterol J Date: 2019-03-19 Impact factor: 4.623
Authors: James D Lord; S Alice Long; Donna M Shows; Jerill Thorpe; Katherine Schwedhelm; Janice Chen; Mariko Kita; Jane H Buckner Journal: Clin Immunol Date: 2018-05-26 Impact factor: 3.969
Authors: Maria Gonzalez-Vivo; Minna K Lund Tiirikainen; Montserrat Andreu; Agnes Fernandez-Clotet; Alicia López-García; Francisca Murciano Gonzalo; Lourdes Abril Rodriguez; Carmen de Jesús-Gil; Ester Ruiz-Romeu; Lídia Sans-de San Nicolàs; Lluis F Santamaria-Babí; Lucía Márquez-Mosquera Journal: Front Med (Lausanne) Date: 2022-06-15
Authors: Robert Battat; Parambir S Dulai; Niels Vande Casteele; Elisabeth Evans; Kelly D Hester; Edvelyn Webster; Anjali Jain; James A Proudfoot; Ara Mairalles; Jennifer Neill; Siddharth Singh; John T Chang; Jesus Rivera-Nieves; William J Sandborn; Brigid S Boland Journal: Inflamm Bowel Dis Date: 2019-01-10 Impact factor: 5.325
Authors: Britt Roosenboom; Ellen G van Lochem; Jos Meijer; Carolijn Smids; Stefan Nierkens; Eelco C Brand; Liselot W van Erp; Larissa G J M Kemperman; Marcel J M Groenen; Carmen S Horjus Talabur Horje; Peter J Wahab Journal: Cells Date: 2020-04-06 Impact factor: 6.600